Search research articles
Contact Us
Filters
Showing results (231-240 of 436) with videos related to
Page
of 44
Sort By:
American Journal of Hematology
|
April 23, 2021
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden
Musa Yilmaz, Naval Daver, Gautam Borthakur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias
Weiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
American Journal of Hematology
|
January 28, 2025
Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals
Jitesh D Kawedia, Caitlin R Rausch, Xiaoqian Liu, et al.
British Journal of Haematology
|
April 6, 2021
Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era
Mithun V Shah, Rima M Saliba, Ankur Varma, et al.
Cancer
|
April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib
Kiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Oren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Frontiers in Oncology
|
August 23, 2021
Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes
Hussein A Abbas, Vakul Mohanty, Ruiping Wang, et al.
American Journal of Hematology
|
March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Fadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
Leukemia & Lymphoma
|
August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years
Catherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
American Journal of Hematology
|
July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
Aziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.
Page
of 44
Search research articles
Search
Showing results (231-240 of 436) with videos related to
Sort By:
Page
of 44
American Journal of Hematology
|
April 23, 2021
FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden
Musa Yilmaz, Naval Daver, Gautam Borthakur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias
Weiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
American Journal of Hematology
|
January 28, 2025
Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals
Jitesh D Kawedia, Caitlin R Rausch, Xiaoqian Liu, et al.
British Journal of Haematology
|
April 6, 2021
Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era
Mithun V Shah, Rima M Saliba, Ankur Varma, et al.
Cancer
|
April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib
Kiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 25, 2024
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Oren Pasvolsky, Rima M Saliba, Uday R Popat, et al.
Frontiers in Oncology
|
August 23, 2021
Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes
Hussein A Abbas, Vakul Mohanty, Ruiping Wang, et al.
American Journal of Hematology
|
March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Fadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
Leukemia & Lymphoma
|
August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years
Catherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
American Journal of Hematology
|
July 24, 2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
Aziz Nazha, Hagop Kantarjian, Farhad Ravandi, et al.
Page
of 44